Theravance Biopharma (TBPH) CFO receives 37,500-share equity grant in Form 4

Rhea-AI Filing Summary

Sawaf Aziz reported acquisition or exercise transactions in this Form 4 filing.

Theravance Biopharma, Inc. reported that its SVP & Chief Financial Officer, Aziz Sawaf, received a grant of 37,500 Ordinary Shares on April 1, 2026. The shares were awarded at a stated price of $0.00 per share, reflecting compensation rather than a market purchase.

Following this award, Mr. Sawaf directly holds 353,623 Ordinary Shares of Theravance Biopharma. This filing records a stock-based compensation grant to a senior executive, not an open-market buy or sell transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Sawaf Aziz

Role SVP & CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	37,500	$0.00	--

Holdings After Transaction: Ordinary Shares — 353,623 shares (Direct)

Footnotes (1)

Key Figures

Share grant to CFO: 37,500 shares Post-transaction holdings: 353,623 shares Grant price per share: $0.00 per share

3 metrics

Share grant to CFO 37,500 shares Ordinary Shares granted on April 1, 2026

Post-transaction holdings 353,623 shares Ordinary Shares directly held after grant

Grant price per share $0.00 per share Award acquisition price for 37,500 Ordinary Shares

Key Terms

Ordinary Shares, grant/award acquisition, Form 4

3 terms

Ordinary Shares financial

"security_title: "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

grant/award acquisition financial

"transaction_action": "grant/award acquisition""

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sawaf Aziz

(Last) (First) (Middle)

C/O THERAVANCE BIOPHARMA US, LLC

901 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	04/01/2026		A		37,500	A	$0	353,623	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Brett A Grimaud, Attorney-in-Fact	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Theravance Biopharma (TBPH) report for Aziz Sawaf?

Theravance Biopharma reported that SVP & Chief Financial Officer Aziz Sawaf received a grant of 37,500 Ordinary Shares. The award was recorded at $0.00 per share, indicating stock-based compensation rather than an open-market transaction.

How many Theravance Biopharma (TBPH) shares does Aziz Sawaf hold after this Form 4?

After the grant, Aziz Sawaf directly holds 353,623 Ordinary Shares of Theravance Biopharma. This total reflects his position following receipt of the 37,500-share award reported in the Form 4 insider filing.

Was the Theravance Biopharma (TBPH) insider transaction a market purchase or sale?

The transaction was a grant or award acquisition of 37,500 Ordinary Shares at $0.00 per share, not a market purchase or sale. It represents equity compensation to SVP & Chief Financial Officer Aziz Sawaf rather than trading activity.

What does the transaction code 'A' mean in the Theravance Biopharma (TBPH) Form 4?

The transaction code 'A' in the Form 4 indicates a grant, award, or other acquisition of shares. For Theravance Biopharma, it reflects 37,500 Ordinary Shares granted to SVP & Chief Financial Officer Aziz Sawaf as stock-based compensation.

Does the Aziz Sawaf Form 4 for Theravance Biopharma (TBPH) involve derivative securities?

No, the reported transaction involves non-derivative Ordinary Shares only. The filing shows a 37,500-share grant at $0.00 per share and a resulting direct holding of 353,623 shares, with no derivative positions listed in the derivative summary.